Literature DB >> 19445767

PCOS.

David Cahill1.   

Abstract

INTRODUCTION: Polycystic ovary syndrome (PCOS) is diagnosed in up to 10% of women attending gynaecology clinics, but the prevalence in the population as a whole is unclear. PCOS has been associated with hirsutism, infertility, acne, weight gain, type 2 diabetes, cardiovascular disease (CVD), and endometrial hyperplasia. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical question: What are the effects of treatments? We searched: Medline, Embase, The Cochrane Library, and other important databases up to December 2007 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA).
RESULTS: We found 24 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions.
CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: finasteride, flutamide, metformin, spironolactone, cyproterone acetate-ethinylestradiol (co-cyprindiol), interventions to achieve weight loss, ketoconazole, and mechanical hair removal.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19445767      PMCID: PMC2907777     

Source DB:  PubMed          Journal:  BMJ Clin Evid        ISSN: 1462-3846


  28 in total

1.  Treatment of hirsutism by finasteride and flutamide in women with polycystic ovary syndrome.

Authors:  L Falsetti; D De Fusco; G Eleftheriou; B Rosina
Journal:  Gynecol Endocrinol       Date:  1997-08       Impact factor: 2.260

2.  Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome.

Authors:  R S Legro; A R Kunselman; A Dunaif
Journal:  Am J Med       Date:  2001-12-01       Impact factor: 4.965

3.  Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.

Authors:  George Mastorakos; Carolina Koliopoulos; George Creatsas
Journal:  Fertil Steril       Date:  2002-05       Impact factor: 7.329

4.  A randomized controlled trial of laser treatment among hirsute women with polycystic ovary syndrome.

Authors:  W J Clayton; M Lipton; J Elford; M Rustin; L Sherr
Journal:  Br J Dermatol       Date:  2005-05       Impact factor: 9.302

5.  Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study.

Authors:  Thomas Tang; Julie Glanville; Catherine J Hayden; Davinia White; Julian H Barth; Adam H Balen
Journal:  Hum Reprod       Date:  2005-09-30       Impact factor: 6.918

Review 6.  Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.

Authors:  A Dunaif
Journal:  Endocr Rev       Date:  1997-12       Impact factor: 19.871

7.  Comparison of finasteride versus flutamide in the treatment of hirsutism.

Authors:  L Falsetti; A Gambera; L Legrenzi; C Iacobello; G Bugari
Journal:  Eur J Endocrinol       Date:  1999-10       Impact factor: 6.664

8.  Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome.

Authors:  R S Legro; D Driscoll; J F Strauss; J Fox; A Dunaif
Journal:  Proc Natl Acad Sci U S A       Date:  1998-12-08       Impact factor: 11.205

9.  Finasteride versus cyproterone acetate-estrogen regimens in the treatment of hirsutism.

Authors:  A Beigi; A Sobhi; F Zarrinkoub
Journal:  Int J Gynaecol Obstet       Date:  2004-10       Impact factor: 3.561

10.  Mortality of women with polycystic ovary syndrome at long-term follow-up.

Authors:  T Pierpoint; P M McKeigue; A J Isaacs; S H Wild; H S Jacobs
Journal:  J Clin Epidemiol       Date:  1998-07       Impact factor: 6.437

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.